KR0137959B1 - 2개의 cpi 소단위를 갖는 신규한 cc-1065 유사화합물 - Google Patents

2개의 cpi 소단위를 갖는 신규한 cc-1065 유사화합물

Info

Publication number
KR0137959B1
KR0137959B1 KR1019900700977A KR900700977A KR0137959B1 KR 0137959 B1 KR0137959 B1 KR 0137959B1 KR 1019900700977 A KR1019900700977 A KR 1019900700977A KR 900700977 A KR900700977 A KR 900700977A KR 0137959 B1 KR0137959 B1 KR 0137959B1
Authority
KR
South Korea
Prior art keywords
dipyrrole
chloromethyl
compound
methylbenzo
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019900700977A
Other languages
English (en)
Korean (ko)
Other versions
KR900701801A (ko
Inventor
씨. 켈리 로보트
에이. 아리스토프 폴
Original Assignee
로버트 에이. 아미테이지
디 업존 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 로버트 에이. 아미테이지, 디 업존 캄파니 filed Critical 로버트 에이. 아미테이지
Publication of KR900701801A publication Critical patent/KR900701801A/ko
Application granted granted Critical
Publication of KR0137959B1 publication Critical patent/KR0137959B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Error Detection And Correction (AREA)
  • Solid State Image Pick-Up Elements (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Artificial Filaments (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Amplifiers (AREA)
  • Semiconductor Integrated Circuits (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Television Systems (AREA)
  • Television Receiver Circuits (AREA)
  • Stereophonic System (AREA)
  • Peptides Or Proteins (AREA)
KR1019900700977A 1988-09-12 1989-08-07 2개의 cpi 소단위를 갖는 신규한 cc-1065 유사화합물 Expired - Fee Related KR0137959B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24335088A 1988-09-12 1988-09-12
US7/243,350 1988-09-12
US07/243,350 1988-09-12
PCT/US1989/003329 WO1990002746A1 (en) 1988-09-12 1989-08-07 Novel cc-1065 analogs having two cpi subunits

Publications (2)

Publication Number Publication Date
KR900701801A KR900701801A (ko) 1990-12-04
KR0137959B1 true KR0137959B1 (ko) 1998-05-15

Family

ID=22918400

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900700977A Expired - Fee Related KR0137959B1 (ko) 1988-09-12 1989-08-07 2개의 cpi 소단위를 갖는 신규한 cc-1065 유사화합물

Country Status (14)

Country Link
US (1) US5541339A (cg-RX-API-DMAC10.html)
JP (1) JP3380237B2 (cg-RX-API-DMAC10.html)
KR (1) KR0137959B1 (cg-RX-API-DMAC10.html)
AT (1) ATE198335T1 (cg-RX-API-DMAC10.html)
AU (1) AU632288B2 (cg-RX-API-DMAC10.html)
CA (1) CA1340215C (cg-RX-API-DMAC10.html)
DE (1) DE68929275T2 (cg-RX-API-DMAC10.html)
DK (1) DK175458B1 (cg-RX-API-DMAC10.html)
FI (1) FI103668B (cg-RX-API-DMAC10.html)
GR (1) GR3035589T3 (cg-RX-API-DMAC10.html)
LV (1) LV12806B (cg-RX-API-DMAC10.html)
NO (1) NO303498B1 (cg-RX-API-DMAC10.html)
TW (1) TW217383B (cg-RX-API-DMAC10.html)
WO (1) WO1990002746A1 (cg-RX-API-DMAC10.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2149768T3 (es) * 1992-03-25 2000-11-16 Immunogen Inc Conjugados de agentes enlazantes de celulas derivados de cc-1065.
US5502068A (en) * 1995-01-31 1996-03-26 Synphar Laboratories, Inc. Cyclopropylpyrroloindole-oligopeptide anticancer agents
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
EP1392359B2 (en) 2001-05-11 2013-03-13 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
CN1612733A (zh) 2001-11-09 2005-05-04 贝林格尔·英格海姆药物公司 用作蛋白激酶抑制剂的苯并咪唑类
JP2005536533A (ja) * 2002-08-08 2005-12-02 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 置換ベンゾイミダゾール化合物
AU2003287160A1 (en) * 2002-10-15 2004-05-04 Rigel Pharmaceuticals, Inc. Substituted indoles and their use as hcv inhibitors
EP1641759B1 (en) * 2003-07-07 2014-03-12 Merck Patent GmbH Malonamide derivatives
US20050209284A1 (en) * 2004-02-12 2005-09-22 Boehringer Ingelheim Pharmaceuticals, Inc. Tec kinase inhibitors
CN101287728A (zh) * 2005-08-17 2008-10-15 先灵公司 新的高亲和力噻吩基和呋喃基激酶配体
ES2609094T3 (es) 2007-01-25 2017-04-18 Dana-Farber Cancer Institute, Inc. Uso de anticuerpos anti-EGFR en el tratamiento de enfermedades mediadas por un EGFR mutante
JP5618549B2 (ja) 2007-03-15 2014-11-05 ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド Ｅｇｆｒ抗体及びｓｒｃ阻害剤を用いる治療方法及び関連製剤
US9901567B2 (en) 2007-08-01 2018-02-27 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
MX2010001757A (es) 2007-08-14 2010-09-14 Ludwig Inst Cancer Res Anticuerpo monoclonal 175 que activa el receptor egf y derivados y usos del mismo.
AU2009320481C1 (en) 2008-11-03 2016-12-08 Syntarga B.V. Novel CC-1065 analogs and their conjugates
WO2011133039A2 (en) 2010-04-21 2011-10-27 Syntarga B.V. Novel conjugates of cc-1065 analogs and bifunctional linkers
US20150265641A1 (en) 2012-10-22 2015-09-24 Arnold Glazier Methods for the Effective Treatment of Metastatic Cancer
DE102013012622A1 (de) * 2013-07-30 2015-02-05 Clariant lnternational Ltd Neue sterisch gehinderte cyclische Amine
MY177390A (en) 2014-01-10 2020-09-14 Byondis Bv Method for purifying cys-linked antibody-drug conjugates
MX371147B (es) * 2014-01-27 2020-01-20 Pfizer Agentes citotoxicos bifuncionales.
US10973920B2 (en) 2014-06-30 2021-04-13 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
DE102015000124A1 (de) * 2015-01-07 2016-07-07 Clariant International Ltd. Verfahren zur Stabilisierung von Polyamiden
US10870706B2 (en) * 2015-03-20 2020-12-22 Pfizer Inc. Bifunctional cytotoxic agents containing the CTI pharmacophore

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4169888A (en) * 1977-10-17 1979-10-02 The Upjohn Company Composition of matter and process
US4301248A (en) * 1979-12-21 1981-11-17 Bristol-Myers Company Fermentation process for making rachelmycin
US4413132A (en) * 1980-11-18 1983-11-01 The Upjohn Company Antibiotic CC-1065 indoline intermediates
US4912227A (en) * 1984-02-21 1990-03-27 The Upjohn Company 1,2,8,8A-tetrahydrocyclopropa(c)pyrrolo(3,2-e)-indol-4-(5H)-ones and related compounds
CA1238907A (en) * 1984-02-21 1988-07-05 Robert C. Kelly 1,2,8,8a-tetrahydrocyclopropa¬c|pyrrolo(3,2-e)- indol-4(5h)-ones and related compounds
GB8528848D0 (en) * 1985-11-22 1985-12-24 Davy Mckee Poole Rolling mills
AU617304B2 (en) * 1986-12-19 1991-11-28 Pharmacia & Upjohn Company Novel cc-1065 analogs

Also Published As

Publication number Publication date
NO910958D0 (no) 1991-03-11
ATE198335T1 (de) 2001-01-15
JPH04500664A (ja) 1992-02-06
GR3035589T3 (en) 2001-06-29
WO1990002746A1 (en) 1990-03-22
JP3380237B2 (ja) 2003-02-24
AU4192289A (en) 1990-04-02
AU632288B2 (en) 1992-12-24
DK175458B1 (da) 2004-11-01
DK41791A (da) 1991-03-08
FI911193A0 (fi) 1991-03-11
TW217383B (cg-RX-API-DMAC10.html) 1993-12-11
DK41791D0 (da) 1991-03-08
LV12806B (lv) 2002-05-20
FI103668B1 (fi) 1999-08-13
NO303498B1 (no) 1998-07-20
FI103668B (fi) 1999-08-13
KR900701801A (ko) 1990-12-04
LV12806A (en) 2002-03-20
DE68929275T2 (de) 2001-05-23
DE68929275D1 (de) 2001-02-01
CA1340215C (en) 1998-12-15
NO910958L (no) 1991-05-10
US5541339A (en) 1996-07-30

Similar Documents

Publication Publication Date Title
KR0137959B1 (ko) 2개의 cpi 소단위를 갖는 신규한 cc-1065 유사화합물
JP5276582B2 (ja) 抗ウイルス剤としての五環インドール誘導体
CA2381885C (en) Isomeric fused pyrrolocarbazoles and isoindolones
US7521443B2 (en) Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
CA2420592C (en) Fused pyrrolocarbazoles against inflammation
AU2016280236B2 (en) Nrf2 regulators
US20070270405A1 (en) Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors
US20070270417A1 (en) Antibacterial Agents
JP2008517986A (ja) 抗ウイルス薬としての四環式インドール誘導体
AU2007361468A1 (en) Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
EP0359454B1 (en) CC-1065 analogs having two CPI subunits
AU613392B2 (en) Imidazo (1,2-b) pyridazin-2-yl carbamate derivatives
US20060100262A1 (en) Tetracyclic indole derivatives as antiviral agents
KR100399704B1 (ko) 축합다환식헤테로환유도체
EP0491814B1 (en) Tetracyclic imidazoquinazoline derivatives, preparation and pharmaceutical compositions
MXPA06007325A (en) Novel fused pyrrolocarbazoles

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

FPAY Annual fee payment

Payment date: 20050630

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20060214

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20060214

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000